Q-omics provides the consensus-scored MKRN2OS profile across patient tissues and cancer cell-line models. MKRN2OS expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, MKRN2OS is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, MKRN2OS RNA expression shows 19,657 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UCEC, KIRC, and UVM as cancer lineages where MKRN2OS shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MKRN2OS — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MKRN2OS survival associations across molecular data types. MKRN2OS RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MKRN2OS RNA expression–survival associations across cancer types. High MKRN2OS expression shows unfavorable associations in ESCA, but favorable associations in UCEC, BLCA, SCLC, BRCA and READ. The UCEC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for MKRN2OS RNA expression.
This table summarizes MKRN2OS tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MKRN2OS. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MKRN2OS shows lower tumor expression in KIRC and HNSC and higher tumor expression in BLCA, LUAD, BRCA and LIHC. The KIRC box plot shows higher MKRN2OS RNA expression in normal versus tumor tissue (log2 FC = −0.883, t-test p < 0.001).
This table shows molecular features associated with MKRN2OS in patient tissues and cancer cell lines. In patient samples, MKRN2OS shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, MKRN2OS RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
